

Date: 10/11/2020

To,
EMERGE PLATFORM OF NSE
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

SYMBOL: AJOONI

Sub.: Approval of Un-Audited Financial Results for the half year ended 30th September, 2020.


Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 10/11/2020 at the Registered Office of the company have considered and approved the Un-Audited Financial Statements for the half year ended 30th September, 2020. In this regards, we are enclosing herewith:

1. Un- Audited Financial Results for the half year ended 30th September, 2020.
2. Auditors' Limited Review Report on Un- Audited Financial Results for the half year ended 30th September, 2020.

You are requested to kindly take the same on record.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited



Swati Vijan
Company Secretary
ACS-39179



AJOONI BIOTECH LIMITED
CIN : U85190PB2010PLCO40162

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30.09.2020 (RS. IN LAKHS)

PARTICULARS	Half Yearly			Yearly	
	30.09.2020 (Unaudited)	31.03.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)	31.03.2019 (Audited)
I Revenue From Operations	2194.20	2356.93	1646.33	4003.26	3971.81
II Other Income	0.73	-8.52	14.51	5.99	33.86
III TOTAL REVENUE (I + II)	2,194.93	2,348.41	1,660.84	4,009.25	4,005.67
IV EXPENSES:					
Cost of Material Consumed	1874.65	1866.01	1446.86	3493.59	3646.48
Purchase of Stock-In-Trade	0.00	0.00	0.00	0.00	0.00
Change In Inventories	-20.69	185.47	-6.27	-2.39	0.72
Finance Cost	20.80	19.29	13.50	32.79	10.71
Employee Benefit Expenses	62.48	45.54	66.26	111.80	72.13
Depreciation and amortization	21.30	17.56	31.63	49.19	43.82
Other Expenses	183.94	177.34	97.96	276.17	184.32
TOTAL EXPENSES	2,142.48	2,311.21	1,649.94	3,961.15	3,958.18
V PROFIT / (LOSS) FROM OPERATION BEFORE EXCEPTIONAL AND EXTRAORDINARY ITEMS AND TAX (III-IV)	52.45	37.20	10.90	48.10	47.49
VI Exceptional Items	0.00	0.00	0.00	0.00	0.00
VII PROFIT / (LOSS) BEFORE EXTRAORDINARY ITEMS AND TAX (V-VI)	52.45	37.20	10.90	48.10	47.49
VIII Extraordinary items	0.00	0.00	0.00	0.00	0.00
IX PROFIT / (LOSS) BEFORE TAX (VII-VIII)	52.45	37.20	10.90	48.10	47.49
X TAX EXPENSE:					
(1) Current Tax	13.60	14.00	2.83	16.83	11.75
(2) Deferred Tax	0.00	3.44	0.00	3.44	-5.35
(3) MAT Credit	0.00	0.00	0.00	0.00	0.00
XI NET PROFIT / (LOSS) FROM CONTINUING OPERATIONS (VII-VIII)	38.85	19.76	8.07	34.71	41.10
XII NET PROFIT / (LOSS) FROM DISCONTINUING OPERATIONS	0.00	0.00	0.00	0.00	0.00
XIII TAX EXPENSE OF DISCONTINUING OPERATIONS	0.00	0.00	0.00	0.00	0.00
XIV NET PROFIT / (LOSS) FROM DISCONTINUING OPERATIONS (after Tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00
XV Profit/Loss for the period(XI+XIV)	38.85	19.76	8.07	34.71	41.10
XVI NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) *	38.85	19.76	8.07	34.71	41.10
XVII Paid-up equity share capital (Face Value of the Share shall be indicated)	840.50	840.50	615.50	840.50	615.50
XVIII Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	840.50	840.50	615.50	840.50	615.50
XIX Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):					
(1) BASIC	0.46	0.24	0.13	0.41	0.67
(2) DILUTED	0.46	0.24	0.13	0.41	0.67
XX Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):					
(1) BASIC	0.46	0.24	0.13	0.41	0.67
(2) DILUTED	0.46	0.24	0.13	0.41	0.67

* Applicable in the case of consolidated results.

Notes:

1. The above Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10th November 2020.

2. Segment Reporting is not applicable, since the company is involved in one segment only

For and on behalf of Board of Ajooni Biotech Limited

Place : Mohali
Date : 10/11/2020



Jasjot Singh
Director
DIN: 01937631


AJOONI BIOTECH LIMITED
CIN : U85190PB2010PLC040162

STATEMENT OF ASSETS AND LIABILITIES

UNDER REGULATION 33 OF THE SEBI(USTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS,
2015

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES (RS. IN LAKHS)

PARTICULARS	30.09.2020	30.09.2019	year ended 31.03.20
	unaudited	unaudited	Audited
<u>I EQUITY AND LIABILITIES</u>			
(1) <u>Shareholders' funds</u>			
(a) Equity Share Capital	840.50	615.50	840.50
(b) Reserves and surplus	787.45	622.03	748.60
(2) <u>Non-Current Liabilities</u>			
(a) Long Term Borrowings	224.93	430.15	133.07
(3) <u>Current Liabilities</u>			
(a) Short Term Borrowings	323.69	207.33	369.46
(b) Trade Payables	253.99	151.44	193.28
(c) Other Current Liabilities	23.25	87.79	4.46
(d) Short Term Provisions	30.43	0.62	17.38
TOTAL Rs.	2,484.24	2,114.86	2,306.75
<u>I. ASSETS</u>			
(1) <u>Non - Current Asset</u>			
(a) Property, Plant and Equipment			
(i) Tangible Assets	251.48	104.33	207.15
(b) Non-Current Investments	296.16	363.02	307.87
(c) Long Term Loans & Advances	36.02	111.72	
(d) Deferred Tax Asset	12.74	9.29	12.74
(e) Other Non Current Assets	21.10	42.21	28.14
(2) <u>Current Assets</u>			
(a) Inventories	349.26	506.00	328.57
(b) Trade Receivables	1,261.91	805.52	1,264.19
(c) Cash & Cash Equivalent	20.92	29.85	12.39
(d) Short Term Loans and advances	213.61	142.91	124.67
(e) Other Current Asset	21.04	-	21.04
TOTAL Rs.	2,484.24	2,114.85	2,306.75





Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Independent Auditor's Limited Review Report on the Half Yearly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,


**The Board of Directors,
Ajooni Biotech Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Ajooni Biotech Limited** ("the Company") for the Half Year ended September 30, 2020 and year to date from April 01, 2020 to September 30, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") read with SEBI Circular No. CIR/CFD/CMDI /44/2019 dated March 29, 2019 ('the Circular').

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors in their meeting held on November 10, 2020, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133, of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on this Financial Statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Harjeet Parvesh & Company
Chartered Accountants
FRN: 017437N

CA Harjeet Singh
FCA
M.No 095466

Place: Mohali

Date: 10th Day of November, 2020

UDIN: 20095466AAAAGJS116.